Vaccine studies using the Vaccine Research Registry

This page lists the NIHR supported vaccine studies that are currently approved to use the Vaccine Research Registry and that you may receive contact about.

All study invitations from the vaccine research registry will be sent to you from NHS COVID-19 Vaccine Research Registry (ccsm@nhsdigital.nhs.uk). Please note however that if you complete a pre-screener for a study, any follow up emails will be from the study team this will be an ac.uk; nhs.uk; nhs.net; nihr.ac.uk address.

We still need your help

There is no change to any of the number of clinical trials into COVID vaccines at the moment, and it is essential that these continue.

We will need data about a number of vaccines and their safety and effectiveness, in order to protect the population. No one vaccine is likely to be suitable for everyone, the first vaccine may not be the most effective and easiest to use, and we must make sure that the other studies continue to allow us to have a selection of vaccines to protect the whole population.

Studies looking for volunteers

AstraZeneca Beta Variant COVID-19 Vaccine Study

Study AZD2816 is researching an investigational COVID-19 vaccine that has been designed specifically against the Beta variant of the SARS-CoV-2 virus, which first emerged in South Africa. The study is also evaluating the Oxford-AstraZeneca vaccine against the Beta variant. Although COVID-19 vaccines are now available in many countries, it is not known how well these vaccines will work against mutated or ‘variant’ forms of the SARS-CoV- 2 virus.

We are looking for volunteers who:

  • are 30 years of age and older
    and
  • have already received 2 doses (3–12 weeks apart) of the Oxford-AstraZeneca, Pfizer-BioNTech, or Moderna COVID-19 vaccine (at least 3 months before receiving the investigational vaccine in this study).

Participants in this study will receive either the investigational vaccine or the Oxford-AstraZeneca vaccine as a single ‘booster’ injection. Study participation is likely to be about 6.5 months, but could vary depending on the vaccine group to which you are assigned.

The study is being conducted at multiple locations in the United Kingdom.

Can I take part?

If you are interested in taking part, please visit www.letsfindavaccine.com, where you can complete a pre- screening questionnaire to see if you might be eligible. Once you have registered your interest, you will be contacted if you fit the volunteer criteria the study team is currently looking for, and if you live in one of the locations where hospitals are currently looking for volunteers for this study.

What email address will be used to contact me about taking part?

You will receive an email notification from AstraZeneca Beta Variant COVID-19 Vaccine Study (ccsm@nhsdigital.nhs.uk). If you decide you are interested in the study and complete the pre-screening questionnaire, the study team may then contact you directly from a different email address (ending ac.uk; nhs.uk; nhs.net; nihr.ac.uk).

Pfizer & BioNTech COVID-19 – Vaccine Maternal Study

Members of the public that meet the criteria for this study are invited to contact the study team directly, the study team is not sending email invitations directly to Vaccine Research Registry volunteers

This study involves comparing an investigational (study) vaccine against a placebo (injection with no active ingredient) to see if the study vaccine produces antibodies in expectant mothers and their babies once born and prevents COVID-19 in expectant mothers. It will also help us collect safety data on the study vaccine.

  • This study will help researchers learn more about how the study vaccine works for pregnant women and their babies.
  • All participants in the study will have the opportunity to receive the active study vaccine either while they are pregnant or shortly after giving birth.

Contact: ClinicalTrials.gov_Inquiries@pfizer.com

See full study details

Studies that are now closed for recruitment

The studies listed below have previously used the NHS COVID-19 Vaccine Research Registry to help identify suitable participants. These vaccine studies have now reached their recruitment target and their results are helping us to learn more about the effectiveness of COVID-19 vaccines.

Valneva Phase 3 Study

The Valneva Phase 3 study is researching whether the Valneva Vaccine VLA2001 induces more neutralizing antibodies against COVID-19 than the AstraZeneca vaccine and that it is safe and well tolerated. We are looking for volunteers who are 18 years of age and older, who are generally healthy and have not received a previous vaccine intended to prevent COVID-19. There are up to 8 study visits over a 1 year period and the study will take place across several locations in the UK.

When will this study contact me?

Contact from this study was approved to start from 21st April 2021. You will be contacted if you fit the criteria the study requires and if you are within easy reach of one of the research sites who are conducting the study.

What email address will be used to contact me about this?

You will receive an email notification from [ccsm@nhsdigital.nhs.uk]. If you are interested in the study and complete the pre-screening questionnaire, then the study team may contact you directly from a different email address – this will be an ac.uk, nhs.uk, nhs.net, nihr.ac.uk or panthera-bio.com email address. You may also be contacted via phone on the number you provided.

Comparing COVID-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2)

We are looking for volunteers to take part in a study looking at what happens in the immune system when a second (boost) dose of COVID-19 vaccine is a different type to the first. We are looking for people who have already had their first dose of COVID-19 vaccine through the NHS vaccine roll out programme. This is being run by the NIHR, and the Oxford Vaccine Group, which is part of the University of Oxford.

If you are aged 50 years and over, and have received only one dose of COVID-19 vaccine from the NHS vaccine programme so far, then you may be eligible to take part in the study. We will provide reimbursement up to for your time, inconvenience and travel. The total study participation time is up to 10 months. If you are interested in finding out more, please visit our website, where you can access the Study Information Booklet.

Medicago COVID-19 Vaccine Study

The Medicago Phase 3 Vaccine Study is now recruiting. This clinical trial aims to test a potential COVID-19 vaccine produced in a form of Coronavirus-like particles (CoVLPs). These CoVLPs are proteins produced by plants that mimic the shape and dimensions of the real virus but cannot cause the disease because they do not have any genetic material.

This large study will determine how effective and safe the Medicago COVID-19 vaccine is at potentially protecting people from COVID-19. We will measure potential protection by taking blood samples to collect information on your immune response.

This is a potential vaccine and it may not work at all. Even if the vaccine does work, we cannot guarantee you will not get COVID-19.

This study will aim to recruit around 30,000 people in the UK (1,500 people in the UK), North America, Europe and Latin America using a cross-over design which means that each participant will receive both the study vaccine and a placebo during the course of the study. This means that in the first part of the trial even though you have been enrolled you could receive a “dummy” vaccine, meaning you are as likely to be infected with COVID-19 as you were before enrolling in the trial.

You may be eligible to participate if you are 18 years old or over and in good general health. Your participation could involve up to 10 visits during a maximum of 26 month total time period at one of our multiple research sites across the UK.

If you are interested in the study, we can discuss with you how to manage a future situation where you have been invited for an NHS approved vaccine; there is no obligation to remain in this study.

When will this study contact me?
Contact from this study was approved to start from (14/04/2021). You will be contacted if you fit the volunteer criteria the study team is currently looking for, and if you live in one of the locations where investigators are currently recruiting for this study.

What email address will be used to contact me about this?
You will receive an email notification from Medicago Vaccine Study (ccsm@nhsdigital.nhs.uk). If you decide you are interested in the study and complete the pre-screening, then the study team may contact you directly from a different email address - this will be an ac.uk; nhs.uk; nhs.net; nihr.ac.uk.

Novavax study

The purpose of this study is to test a new vaccine against COVID-19 and we are looking for volunteers to take part.  If you are aged 18-84 and in good health, you could be eligible to participate.  The study involves 6 visits over a period of around 13 months.  This study is being conducted across multiple locations in the UK.

When will this study contact me?

Contact from this study was approved to start from 1 October 2020. You will be contacted if you fit the volunteer criteria the study team is currently looking for, and if you live in one of the locations where hospitals are currently looking for volunteers for this study. 

What email address will be used to contact me about this?

You will receive an email notification from Novavax Covid 19 Vaccine Study (ccsm@nhsdigital.nhs.uk)If you decide you are interested in the study and complete the pre-screening, then the study team may contact you directly from a different email address - this will be an ac.uk; nhs.uk; nhs.net; nihr.ac.uk.

Oxford study

The COVID-19 Oxford Vaccine Trial aims to find a safe vaccine that can be used to create immune responses against the virus and thus prevent the disease. The study involved healthy volunteers aged 56 years and over who will attend 7 visits over 13 months.  If you volunteered, you will be contacted if you fit the volunteer criteria the study team is currently looking for, and if you live in one of the locations where hospitals are currently looking for volunteers for this study. 

What email address will be used to contact me about this?

You will receive an email notification from oxfordvaccinestudy@nhs.net. If you decide you are interested in the study and complete the pre-screening, then the study team may contact you directly from a different email address - this will be an ac.uk; nhs.uk; nhs.net; nihr.ac.uk.  

PROVENT Study

The PROVENT Study is researching a combination of two investigational monoclonal antibodies for the prevention of COVID-19. We are looking for volunteers who are 18 years of age and older and at an increased risk of exposure to COVID-19 (due to location, employment, or personal circumstances) to take part. The study involves 8 visits over 1 year and is being conducted at multiple locations in the UK.

When will this study contact me?

Contact from this study was approved to start from 18 December 2020. You will be contacted if you fit the volunteer criteria the study team is currently looking for, and if you live in one of the locations where hospitals are currently looking for volunteers for this study. 

What email address will be used to contact me about this?

You will receive an email notification from the PROVENT COVID-19 Study at ccsm@nhsdigital.nhs.uk. If you decide you are interested in the study and complete the pre-screening, then the study team may contact you directly from a different email address ‒ this will be an ac.uk, nhs.uk, nhs.net, or nihr.ac.uk email address.

Valneva Study

A new COVID-19 vaccine study is starting and looking for healthy adult volunteers to participate.  The study is sponsored by Valneva Austria GmbH. The major eligibility criteria are as follows:

-        Between 18 to 55 years of age

-        Generally healthy with a Body Mass Index (BMI) of 18-30

The study, VLA2001-201, is testing a new vaccine candidate to prevent COVID-19 across several hospitals in the UK. The study is evaluating the investigational vaccine to confirm that it is safe and tolerable for the users.

If you take part in this study, you will receive the investigational vaccine either in the low, medium or high concentration dose at no costs and you will be compensated for your time.

There will be a screening visit, two vaccination visits, 3 weeks apart and a number of follow-up visits to attend. Study related activities will include physical examination, COVID-19 testing, blood and urine samples. In total, your participation is required for about 7 months.

Comparing COVID-19 Vaccine Schedule Combinations (Com-COV) Study

We are recruiting people 50 years of age and over to a study of ‘mixed’ schedules of different COVID-19 vaccines.

There are now a number of vaccines that have been approved to prevent COVID-19 in the UK. These use two-doses, a ‘prime’ first dose, followed by a ‘boost’ second dose some weeks later. The purpose of this trial is to see how well people’s immune systems respond when they are primed with one type of vaccine, then boosted with another and to see how good the response is when the second dose is separated from the first dose by different periods of time.

The trial will take one year to complete per participant (from the time the first dose of vaccine is given).

If you are interested in finding out more, please visit our website: www.comcovstudy.org.uk where you can access the Study Information Booklet.

Janssen COVID-19 Study

Janssen is recruiting volunteers for a COVID-19 vaccine study in the UK. The purpose of this clinical study is to determine the efficacy (whether it works) and safety of an investigational vaccine for the prevention of COVID-19.

This investigational vaccine is being evaluated in people 18 years of age or older.

For more information visit: https://gb.ensemblestudy.com

When will the study contact me?

Contact for this study was approved to start from November 10th 2020. You will be contacted if you fit the volunteer criteria the study team is currently looking for, and if you live in one of the locations where hospitals are currently looking for volunteers for this study.

What email address will be used to contact me about this?

You will receive an email notification from ccsm@nhsdigital.nhs.uk. If you decide you are interested in the study and complete the pre-screening, then the study team may contact you directly from a different email address - this will be an ac.uk; nhs.uk; nhs.net; nihr.ac.uk.